何立儒副主任醫(yī)師
中山大學附屬腫瘤醫(yī)院放療科
工作與學習經(jīng)歷：2007年畢業(yè)于中山大學臨床醫(yī)學七年制;主要從事泌尿系統(tǒng)腫瘤和胸部腫瘤的研究和臨床治療。2011年入選中山大學腫瘤防治中心優(yōu)才計劃培養(yǎng)對象;2013年以國家公派身份到美國M.D.Anderson癌癥中心進修1年，針對泌尿系統(tǒng)和胸部腫瘤放療的前沿技術(shù)進行了系統(tǒng)學習;2015年擔任我院前列腺癌MDT團隊放療會診專家;同年獲聘中國抗癌協(xié)會泌尿腫瘤系統(tǒng)專業(yè)委員會青年委員。 研究方向與業(yè)績：主要從事泌尿系統(tǒng)腫瘤和胸部腫瘤的研究和臨床治療。先后發(fā)表SCI論文30余篇，其中以第一作者和并列第一作者身份發(fā)表SCI論文13篇(5分以上7篇)。作為項目負責人獲得國家自然科學基金1項，中山大學優(yōu)秀人才項目1項;作為主要成員參加國家自然科學基金2項以及廣東省級科研基金7項。 主要科研項目 (1) 國家自然科學基金(青年項目)：AIB1在肺腺癌轉(zhuǎn)移中的作用及分子機制(81201842)。24萬元。2013.1～2015.12。項目負責人。 (2) 中山大學腫瘤防治中心優(yōu)秀青年人才培養(yǎng)計劃基金：AIB1在食管鱗癌放射抵抗中的作用及分子機制。5萬元/年。2011.1～2015.12。項目負責人。 (3) 國家自然科學基金(青年項目)：miR-130b在肝細胞癌發(fā)病中的作用及其表達調(diào)控機制(81101863)。23萬元。2012.1～2014.12。第二申請人。 門診時間：每周一下午 電話：020-87342250 主要代表作 (1) He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol. 2010;21(8):1675-81. (2) He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ, Xie D. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 2015; 6(31):31181-90. (3) He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014; 9(9):1398-405 (4) He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer. 2011; 129(1):143-50. (5) He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010;127(1):138-47. (6) He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX, Xie D. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009;100(9):1591-6. ( (7) He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Zhang LJ, Guan XY, Zeng YX, Xie D. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009;100(12):2354-60. (8) He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:461. (9) He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer. 2015; 15:1095. (10) Qian D, Zhang B, He LR(并列第一作者), Cai MY, Mai SJ, Liao YJ, Liu YH, Lin Marie C., Bian XW, Zeng YX, Huang JJ, Kung HF, and XieD. The Telomere/Telomerase Binding Factor PinX1 is a New Target to Improve the Radiotherapy Effect of Esophageal Squamous Cell Carcinomas. J Pathol. 2013; 229(5):765-74. (11) Tian XP, Qian D, He LR(并列第一作者), Huang H, Mai SJ, Li CP, Huang XX, Cai MY, Liao YJ, Kung HF, Zeng YX, Xie D. The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas. Cancer Lett. 2014; 353(1):104-14. (12) Liu JY, Qian D, He LR(并列第一作者), Li YH, Liao YJ, Mai SJ, Tian XP, Liu YH, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Mol Cancer. 2013; 12(1):148. (13) Cao X, He LR (并列第一作者), Xie FY, Chen YF, Wen ZS. Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit? BMC Cancer. 2011; 11:370. (14) 何立儒, 劉孟忠. 前列腺癌的外照射放療進展. 國際腫瘤學雜志. 2008; 35(7):533-6.
?
